# Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

> **NCT05278728** · PHASE1,PHASE2 · COMPLETED · sponsor: **Biotech Pharmaceutical Co., Ltd.** · enrollment: 31 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT05278728
- **Lead sponsor:** Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2013-08
- **Final completion:** 2013-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05278728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05278728, "Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05278728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*